Drug Trial Radar · NCT07023731
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
May 29, 2025
Primary completion
Oct 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Arvinas Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-806. Researchers think that ARV-806 can work by breaking down a specific protein with a mutation that is present in some tumors, which might help prevent or slow tumors from growing. This will be the first time ARV-806 will be used in people. The investigational drug will be given through a vein. This is called intravenous (IV) infusion. This study will include 2 parts: In Part A (Phase 1), different small groups of participants will receive lower to higher doses of ARV-806. Adults with advanced cancers having a specific KRAS mutation will be included. In Part B (Phase 2), participants will be assigned to receive one of up to 2 dose levels decided by the information from Part A. Part B will include participants with advanced pancreatic ductal cancer having a specific KRAS mutation.
Conditions
- KRAS G12D Mutation
- Advanced Solid Cancer
Interventions
ARV-806Drug
Intravenous infusion at assigned dose and dosing schedule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806Time frame: 28 days from first ARV-806 administration
- Part A (Phase 1): Number of participants with AEsTime frame: From the study baseline to at least 28 days after last dose of ARV-806
- Part B (Phase 2): Overall Response Rate (ORR)Time frame: Approximately 2 years
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Phoenix, Arizona
Clinical Trial Site
Phoenix, Arizona
Clinical Trial Site
New Haven, Connecticut
Clinical Trial Site
Tampa, Florida
Clinical Trial Site
Indianapolis, Indiana
Clinical Trial Site
Grand Rapids, Michigan
Clinical Trial Site
New York, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
Huntersville, North Carolina
Clinical Trial Site
Cleveland, Ohio
Clinical Trial Site
Houston, Texas
Clinical Trial Site
San Antonio, Texas
Clinical Trial Site
Salt Lake City, Utah
Clinical Trial Site
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.